Drug duo vs. solo: battle to keep liver cancer at bay after surgery
NCT ID NCT05367687
Summary
This study tested whether adding a second drug (rivoceranib) to a standard immunotherapy (camrelizumab) is better at preventing liver cancer from returning after initial surgery or ablation. It involved 251 patients who were at high risk of their cancer coming back. The goal was to see which treatment combination kept patients cancer-free for longer and was safe to use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AT HIGH RISK OF RECURRENCE AFTER CURATIVE RESECTION OR ABLATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.